GlassScriptPhysician profile
Jeffrey Angell
NPI 1497002877
$2,207.86
in general payments reported to CMS, 2019-2025
29 companies · $789 in 2025
The $789 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $294 · 2023: $427 · 2024: $698 · 2025: $789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,914.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,913.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $330.25 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $314.00 | 2023-2025 | |
| Glaxosmithkline, LLC. | $239.48 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $156.97 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $113.42 | 2024-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.15 | 2022-2025 | Xifaxan, Trulance |
| Dexcom, INC. | $105.82 | 2024-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.81 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Antares Pharma, INC. | $89.32 | 2024-2025 | Xyosted |
| Verity Pharmaceuticals INC. | $69.88 | 2024-2025 | Tlando |
| Biohaven Pharmaceutical Holding Company LTD. | $69.70 | 2022 | |
| Inspire Medical Systems, INC. | $68.85 | 2025 | Inspire |
| Abbvie INC. | $60.04 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $54.04 | 2024-2025 | Airsupra, Farxiga |
| Corcept Therapeutics | $41.54 | 2025 | Korlym |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $37.45 | 2023-2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $29.83 | 2022-2023 | Trintellix |
| Abiomed | $23.21 | 2025 | |
| Halozyme INC | $21.54 | 2023 | |
| Phathom Pharmaceuticals, INC. | $21.50 | 2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $20.75 | 2024 | Rexulti |
| Paratek Pharmaceuticals, INC. | $19.71 | 2022 | |
| Merck Sharp & Dohme LLC | $19.29 | 2025 | Lagevrio |
| Seqirus USA INC | $17.92 | 2022 | |
| Exact Sciences Corporation | $17.43 | 2024 | Cologuard Collection Kit |
| Edwards Lifesciences Corporation | $15.72 | 2025 | Sapien 3 Ultra Resilia |
| Jazz Pharmaceuticals INC. | $15.68 | 2022 | |
| Axsome Therapeutics, INC. | $15.07 | 2023 | Auvelity |
| Acella Pharmaceuticals, LLC | $14.49 | 2025 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Angell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.